Citigroup analyst Jim Suva upgrades Celestica (NYSE:CLS) from Sell to Neutral and announces $10 price target.
Cantor Fitzgerald Initiates Coverage On Theratechnologies with Overweight Rating, Announces Price Target of $9
Cantor Fitzgerald analyst Louis Chen initiates coverage on Theratechnologies (NASDAQ:THTX) with a Overweight rating and announces Price Target of $9.